Business

US teen finds drugs linked to Alzheimer’s research

By Sohail Khan 26 August 2026, 10:46 pm

Benchmarks
Nifty24,207.75-126.8

FEATURED FUNDS★★★★★

Motilal Oswal Midcap Fund Direct-Growth

5Y Return
24.16 %

Invest Now

Enter search text:

Business News›News›International›Global Trends›17-year-old Connecticut student found 2 FDA-approved drugs that could help fight Alzheimer’s: How his surprising discovery works

Read Today's Paper

17-year-old Connecticut student found 2 FDA-approved drugs that could help fight Alzheimer’s: How his surprising discovery works
Synopsis

A 17-year-old Connecticut student, Leon Wang, identified two FDA-approved lung-scarring drugs that reduced Alzheimer’s-linked cellular damage in lab-grown brain blood-vessel cells. His research offers a promising new clue into how APOE4 and the TGFβ pathway may contribute to Alzheimer’s disease, while raising the possibility that existing medicines could eventually be repurposed for brain health.

A 17-year-old Connecticut student has identified two FDA-approved drugs that could potentially help reduce Alzheimer’s-related damage in brain cells, after investigating a biological pathway linked to one of the strongest genetic risk factors for the disease.

Leon Wang, a student at King School in Stamford, studied whether medicines already approved for other conditions could be repurposed to target cellular changes associated with Alzheimer’s. His research focused on APOE4, a gene variant known to be the strongest genetic risk factor for Alzheimer’s disease.

ALSO READ: Where will Prince Harry and Meghan Markle live in the UK?

The two drugs he identified are nintedanib and pirfenidone, both already approved for treating lung scarring. In Wang’s laboratory-grown brain-cell model, the drugs reduced signs of damage associated with an overactive cellular signaling pathway.

The discovery earned Wang eighth place and a $60,000 award in the 2026 Regeneron Science Talent Search, one of the country's most prestigious science competitions for high school students.

What did Leon Wang discover?

Wang wanted to understand why APOE4 increases the risk of Alzheimer’s. Using publicly available data, he confirmed earlier research showing that people carrying APOE4 had increased activity in a signaling pathway involving transforming growth factor beta, or TGFβ, in cells lining blood vessels in the brain.

ALSO READ: MacKenzie Scott has given away 5 times more than Jeff Bezos despite his $280 billion net worth, 8x greater fortune and 13x more Amazon stock

He then created laboratory models of these brain blood-vessel cells. His experiments showed that excessive TGFβ activity damaged the cells, suggesting that the pathway could be one mechanism connecting APOE4 with harmful changes associated with Alzheimer’s.

The surprising part: He looked at existing drugs

Rather than trying to develop a completely new Alzheimer’s drug, Wang took a different approach. He looked for medicines that could already influence the TGFβ pathway and identified nintedanib and pirfenidone.

Both drugs are FDA-approved treatments for lung scarring, including conditions involving pulmonary fibrosis. Wang then tested them in his laboratory-grown cell model.

ALSO READ: Putin preparing to attack Europe?

The results were striking: both drugs reduced signs of cellular damage caused by excessive TGFβ activity in the model. This approach is known as drug repurposing—investigating whether a medicine developed for one disease might also have applications in another.

Why repurposing existing drugs matters

Developing a completely new medicine can take years and require extensive research and testing. Existing drugs already have safety and pharmacological information from their approved uses. That does not mean they can automatically be prescribed for another disease, but it can give researchers a starting point for investigating new possibilities.

ALSO READ: 'When is my mom coming back home?': Wife of active-duty US Army soldier deported to Honduras after ICE detention in front of daughter following Walmart trip

For Alzheimer’s research, this could be particularly valuable because scientists are still trying to understand the many biological processes involved in the disease.

Wang's work suggests that brain blood-vessel cells and the TGFβ pathway may deserve more attention in Alzheimer’s research, particularly in connection with APOE4.

Does this mean the drugs can treat Alzheimer’s?

Not yet. This is an early-stage laboratory finding, not evidence that nintedanib or pirfenidone can prevent, treat or reverse Alzheimer’s disease in people.

Wang tested the drugs using lab-grown cells, rather than patients. Much more research would be required, including additional laboratory studies and clinical trials, before researchers could determine whether either medicine is safe and effective for Alzheimer’s patients.

Still, the project demonstrates why drug repurposing can be an intriguing route in medical research.

For Wang, the breakthrough was not creating a brand-new medicine. It was asking whether two familiar drugs could have an entirely different purpose—and finding a potential connection worth investigating further.

Add as a Reliable and Trusted News Source
Add Now!

(You can now subscribe to our WhatsApp channel)

(You can now subscribe to our WhatsApp channel)

Read More News on
Leon WangAlzheimer’s diseaseAlzheimer’s researchnintedanibpirfenidoneAPOE4 geneTGFβ pathwaydrug repurposingbrain cells

Enter search text:

Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories

& personalised newsletters
Login Now

Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &

in-depth stock reports
Subscribe Now

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Subscribe to gain powerful insights on business, stock market and industry trends.

Big Price Drop! Flat 40% Off

Student Only Offer

Already a Member? Sign In now

Already a Member? Sign In now
Already a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail Offer
Avail Offer

Claim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004

' + h3 + '

' + h4 + '

' + listing + '

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with in-depth insights that matter

Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

The problem with lab grown diamonds
Why a falling rupee is a better option for the economy

A list of top 20 momentum stocks that have delivered massive returns in one year